Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular degeneration, ...

Age-related macular degeneration (AMD) is one of the leading causes of vision loss among adults over 65. This condition ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) are the leading causes of vision impairment in elderly patients and people living with diabetes, respectively.

If you're apprehensive about getting an intravitreal injection for age-related macular degeneration (AMD), you're not alone. Ophthalmologist Monika Fleckenstein, MD, explains the procedure, how it can ...

An international collaboration of scientists publishing in Nature Reviews Disease Primers this week advocate for a new way of thinking about and finding treatments for age-related macular degeneration ...

Conditions that resemble age-related macular degeneration (AMD) can differ considerably from AMD regarding prognosis, inheritance, monitoring and therapy. Differential diagnoses of AMD include other ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

The 2024 American Academy of Ophthalmology (AAO) Preferred Practice Patterns provide guidance for physicians about best practices in the treatment of age-related macular degeneration (AMD). The ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

The overall dry AMD market size in the US is anticipated to increase, due to the uptake of recently approved therapies, the launch of emerging therapies such as Gildeuretinol (Alkeus Pharmaceuticals), ...